AMF Tjanstepension AB Acquires 83,487 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Posted by Geri Gentry on May 19th, 2026

AMF Tjanstepension AB increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 133.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 145,949 shares of the pharmaceutical company’s stock after buying an additional 83,487 shares during the quarter. AMF Tjanstepension AB’s holdings in Vertex Pharmaceuticals were worth $66,167,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Hartford Funds Management Co LLC lifted its stake in shares of Vertex Pharmaceuticals by 96.9% during the 4th quarter. Hartford Funds Management Co LLC now owns 3,073 shares of the pharmaceutical company’s stock worth $1,394,000 after acquiring an additional 1,512 shares during the last quarter. Capstone Capital Management Ltd bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $219,000. Profund Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 9.2% during the 4th quarter. Profund Advisors LLC now owns 28,818 shares of the pharmaceutical company’s stock worth $13,065,000 after acquiring an additional 2,423 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 37.0% during the 4th quarter. ProShare Advisors LLC now owns 457,046 shares of the pharmaceutical company’s stock worth $207,206,000 after acquiring an additional 123,314 shares during the last quarter. Finally, HighTower Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 8.1% during the 4th quarter. HighTower Advisors LLC now owns 47,559 shares of the pharmaceutical company’s stock worth $21,561,000 after acquiring an additional 3,544 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:VRTX opened at $436.58 on Tuesday. The company has a market capitalization of $110.80 billion, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 1.87 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $507.92. The firm has a 50 day moving average of $445.08 and a 200 day moving average of $450.71.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. Vertex Pharmaceuticals’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.06 earnings per share. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.97 EPS for the current year.

Insider Buying and Selling

In related news, EVP Amit Sachdev sold 58,613 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $468.83, for a total value of $27,479,532.79. Following the completion of the transaction, the executive vice president owned 58,934 shares of the company’s stock, valued at $27,630,027.22. The trade was a 49.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jonathan Biller sold 945 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $459,600.75. Following the completion of the transaction, the executive vice president directly owned 13,659 shares of the company’s stock, valued at $6,643,054.65. This trade represents a 6.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 79,802 shares of company stock valued at $37,402,568 over the last ninety days. Company insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VRTX. Stifel Nicolaus lifted their price target on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Bank of America lifted their price target on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Citigroup lifted their price target on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Canaccord Genuity Group decreased their price target on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Finally, Scotiabank lifted their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $555.17.

Check Out Our Latest Analysis on Vertex Pharmaceuticals

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.